Precigen’s Financial Tightrope: Balancing R&D Investment and Funding Challenges Amid Economic Headwinds

Precigen, Inc. (PGEN) has disclosed a new risk, in the Debt & Financing category.

Precigen, Inc. faces significant financial hurdles as it continues its extensive cash-consuming operations since inception, primarily funneled into research and development as well as gearing up for potential commercialization of its product candidates. The company’s future capital needs are influenced by a myriad of factors, including the progression of its programs, regulatory approvals, strategic transactions, and the management of its intellectual property. Despite raising approximately $72.8 million in January 2023, Precigen may encounter difficulties securing additional funding, potentially leading to dilution of existing shareholders, operational constraints, or unfavorable strategic partnerships. Current economic headwinds further compound these challenges, potentially affecting Precigen’s ability to successfully navigate the capital markets and execute its business strategy.

The average PGEN stock price target is $10.00, implying 594.44% upside potential.

To learn more about Precigen, Inc.’s risk factors, click here.